Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor

[1]  M. Beckmann,et al.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015) , 2015, Geburtshilfe und Frauenheilkunde.

[2]  F. Heitz,et al.  Operative and Conservative Treatment of Uterine Sarcomas. , 2014, Geburtshilfe und Frauenheilkunde.

[3]  J. Sehouli,et al.  Current and future options in the management and treatment of uterine sarcoma , 2014, Therapeutic advances in medical oncology.

[4]  C. Haie-meder,et al.  A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Abdah-bortnyak,et al.  Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. , 2012, International journal of radiation oncology, biology, physics.

[6]  J. Palacios,et al.  Pathologic and molecular features of uterine carcinosarcomas. , 2010, Seminars in diagnostic pathology.

[7]  A. Munkarah,et al.  Ovarian and Uterine Carcinosarcomas: A Comparative Analysis of Prognostic Variables and Survival Outcomes , 2010, International Journal of Gynecologic Cancer.

[8]  J. Prat,et al.  Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. , 2009, Human pathology.

[9]  M. Andujar,et al.  Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  J. Tward,et al.  Does Radiotherapy or Lymphadenectomy Improve Survival in Endometrial Stromal Sarcoma? , 2009, International Journal of Gynecologic Cancer.

[11]  Rochelle L. Garcia,et al.  Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  F. Collin,et al.  Prognostic Factors in Early-Stage Leiomyosarcoma of the Uterus , 2009, International Journal of Gynecologic Cancer.

[13]  J. Prat.  FIGO staging for uterine sarcomas , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  J. Nesland,et al.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients , 2009, Histopathology.

[15]  Jason D. Wright,et al.  The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. , 2008, American journal of obstetrics and gynecology.

[16]  N. Mitra,et al.  Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. , 2008, Gynecologic oncology.

[17]  J. Chan,et al.  Endometrial stromal sarcoma: a population-based analysis , 2008, British Journal of Cancer.

[18]  F. Farrokhyar,et al.  A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.

[19]  D. Gaffney,et al.  The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Yong-Man Kim,et al.  Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007 , 2008, Journal of Cancer Research and Clinical Oncology.

[21]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[22]  A. Gadducci,et al.  The management of patients with uterine sarcoma: a debated clinical challenge. , 2008, Critical reviews in oncology/hematology.

[23]  A. Wolfson,et al.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. , 2007, Gynecologic oncology.

[24]  R. Barakat,et al.  Prognostic Features of Surgical Stage I Uterine Carcinosarcoma , 2007, The American journal of surgical pathology.

[25]  B. van Calster,et al.  Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma , 2007, British Journal of Cancer.

[26]  L. Gilbert,et al.  Prognostic factors and outcome in women with uterine sarcoma. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  Beth Y Karlan,et al.  Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas , 2005, Obstetrics and gynecology.

[28]  N. Umesaki,et al.  Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990–2003) , 2005, International Journal of Gynecologic Cancer.

[29]  S. Regauer,et al.  Should lymphadenectomy be performed in patients with endometrial stromal sarcoma? , 2005, Gynecologic oncology.

[30]  M. Plante,et al.  Lymph node metastases in low-grade endometrial stromal sarcoma. , 2005, Gynecologic oncology.

[31]  M. Zhan,et al.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. , 2004, Gynecologic oncology.

[32]  S. Cha,et al.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy , 2003 .

[33]  J. Růžičková,et al.  Treatment of uterine sarcoma , 2002, Archives of Gynecology and Obstetrics.

[34]  L. Ramondetta,et al.  Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. , 2001, International journal of radiation oncology, biology, physics.

[35]  R. Blom,et al.  Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[36]  E. Pettersen,et al.  The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. , 1996, Gynecologic oncology.

[37]  J. Dunn,et al.  Retrospective analysis of 318 cases of uterine sarcoma. , 1991, European journal of cancer.

[38]  C. Mangan,et al.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Morley,et al.  Prognostic Features of Sarcomas and Mixed Tumors of the Endometrium , 1984, Obstetrics and gynecology.

[40]  J. Prat,et al.  Uterine sarcomas: a review. , 2010, Gynecologic Oncology.

[41]  J. Růžičková,et al.  Treatment of uterine sarcoma. A survey of 49 patients. , 2002, Archives of gynecology and obstetrics.

[42]  A. Markoe,et al.  A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. , 1994, Gynecologic oncology.